HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preferential expression and function of voltage-gated, O2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells.

Abstract
Hypoxic pulmonary vasoconstriction (HPV) is initiated by inhibition of O2-sensitive, voltage-gated (Kv) channels in pulmonary arterial smooth muscle cells (PASMCs). Kv inhibition depolarizes membrane potential (E(M)), thereby activating Ca2+ influx via voltage-gated Ca2+ channels. HPV is weak in extrapulmonary, conduit pulmonary arteries (PA) and strong in precapillary resistance arteries. We hypothesized that regional heterogeneity in HPV reflects a longitudinal gradient in the function/expression of PASMC O2-sensitive Kv channels. In adult male Sprague Dawley rats, constrictions to hypoxia, the Kv blocker 4-aminopyridine (4-AP), and correolide, a Kv1.x channel inhibitor, were endothelium-independent and greater in resistance versus conduit PAs. Moreover, HPV was dependent on Kv-inhibition, being completely inhibited by pretreatment with 4-AP. Kv1.2, 1.5, Kv2.1, Kv3.1b, Kv4.3, and Kv9.3. mRNA increased as arterial caliber decreased; however, only Kv1.5 protein expression was greater in resistance PAs. Resistance PASMCs had greater K+ current (I(K)) and a more hyperpolarized E(M) and were uniquely O2- and correolide-sensitive. The O2-sensitive current (active at -65 mV) was resistant to iberiotoxin, with minimal tityustoxin sensitivity. In resistance PASMCs, 4-AP and hypoxia inhibited I(K) 57% and 49%, respectively, versus 34% for correolide. Intracellular administration of anti-Kv1.5 antibodies inhibited correolide's effects. The hypoxia-sensitive, correolide-insensitive I(K) (15%) was conducted by Kv2.1. Anti-Kv1.5 and anti-Kv2.1 caused additive depolarization in resistance PASMCs (Kv1.5>Kv2.1) and inhibited hypoxic depolarization. Heterologously expressed human PASMC Kv1.5 generated an O2- and correolide-sensitive I(K) like that in resistance PASMCs. In conclusion, Kv1.5 and Kv2.1 account for virtually all the O2-sensitive current. HPV occurs in a Kv-enriched resistance zone because resistance PASMCs preferentially express O2-sensitive Kv-channels.
AuthorsStephen L Archer, Xi-Chen Wu, Bernard Thébaud, Ali Nsair, Sebastien Bonnet, Ben Tyrrell, M Sean McMurtry, Kyoko Hashimoto, Gwyneth Harry, Evangelos D Michelakis
JournalCirculation research (Circ Res) Vol. 95 Issue 3 Pg. 308-18 (Aug 06 2004) ISSN: 1524-4571 [Electronic] United States
PMID15217912 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • KCNA5 protein, human
  • Kcna5 protein, rat
  • Kcnb1 protein, rat
  • Kv1.5 Potassium Channel
  • Peptides
  • Potassium Channels, Voltage-Gated
  • Recombinant Fusion Proteins
  • Scorpion Venoms
  • Shab Potassium Channels
  • Triterpenes
  • correolide
  • tityustoxin
  • iberiotoxin
  • 4-Aminopyridine
  • Acetylcholine
  • Potassium
  • Oxygen
Topics
  • 4-Aminopyridine (pharmacology)
  • Acetylcholine (pharmacology)
  • Animals
  • Cell Hypoxia
  • Cells, Cultured (drug effects, physiology)
  • Gene Expression Regulation
  • Humans
  • Hypoxia (physiopathology)
  • Ion Channel Gating (drug effects)
  • Ion Transport (drug effects)
  • Kv1.5 Potassium Channel
  • Male
  • Membrane Potentials (drug effects)
  • Muscle, Smooth, Vascular (pathology)
  • Myocytes, Smooth Muscle (drug effects, physiology)
  • Oxygen (pharmacology)
  • Patch-Clamp Techniques
  • Peptides (pharmacology)
  • Potassium (metabolism)
  • Potassium Channels, Voltage-Gated (biosynthesis, genetics, physiology)
  • Pulmonary Artery (pathology)
  • Pulmonary Circulation (drug effects, physiology)
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Fusion Proteins (physiology)
  • Scorpion Venoms (pharmacology)
  • Shab Potassium Channels
  • Transduction, Genetic
  • Triterpenes (pharmacology)
  • Vascular Resistance (drug effects, physiology)
  • Vasoconstriction (drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: